DNDi Begins Quest For Sub-$200 Hep C Combo With Malaysia Trial Plan
This article was originally published in PharmAsia News
Executive Summary
DNDi is implementing a major new initiative in hepatitis C through a collaboration with Malaysia's Ministry of Health that aims to begin clinical trials this year to investigate new "affordable" direct-acting combination therapies, with the ultimate of getting the cost of a 12-week course to below $200.